MapLight Therapeutics, Inc. SEC filings MPLT

MapLight Therapeutics, Inc. has 209 filings in SEC EDGAR's recent list, going back to Mar 8, 2019. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 13, 2026 (material agreement, results of operations, unregistered share sale, regulation fd disclosure). The company's fiscal year ends on December 31.

MapLight Therapeutics, Inc. SEC filings
Form Description Filed Period
4 Insider transaction Oct 16, 2026 Oct 15, 2026
4 Insider transaction Oct 16, 2026 Oct 15, 2026
4 Insider transaction Oct 16, 2026 Oct 15, 2026
4 Insider transaction Oct 16, 2026 Oct 15, 2026
4 Insider transaction Oct 16, 2026 Oct 15, 2026
4 Insider transaction Oct 16, 2026 Oct 15, 2026
144 Notice of proposed sale Oct 15, 2026 —
144 Notice of proposed sale Oct 15, 2026 —
144 Notice of proposed sale Oct 15, 2026 —
144 Notice of proposed sale Oct 15, 2026 —
144 Notice of proposed sale Oct 15, 2026 —
144 Notice of proposed sale Oct 15, 2026 —
144 Notice of proposed sale Oct 15, 2026 —
EFFECT Filing Sep 23, 2026 —
424B3 Prospectus Sep 23, 2026 —
S-1/A Amended registration statement Sep 18, 2026 —
4 Insider transaction Sep 18, 2026 Sep 16, 2026
144 Notice of proposed sale Sep 16, 2026 —
S-1 Registration statement Sep 9, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Aug 20, 2026 —
4 Insider transaction Aug 19, 2026 Aug 17, 2026
4 Insider transaction Aug 19, 2026 Aug 17, 2026
4 Insider transaction Aug 19, 2026 Aug 17, 2026
4 Insider transaction Aug 19, 2026 Aug 17, 2026
4 Insider transaction Aug 19, 2026 Aug 17, 2026
4 Insider transaction Aug 19, 2026 Aug 17, 2026
4 Insider transaction Aug 18, 2026 Aug 14, 2026
SCHEDULE 13D/A Amended ownership over 5% (active) Aug 18, 2026 —
10-Q Quarterly report Aug 13, 2026 Jun 30, 2026
8-K Current report
Material agreement, Results of operations, Unregistered share sale, Regulation FD disclosure
Aug 13, 2026 Aug 13, 2026
4 Insider transaction Aug 4, 2026 Aug 3, 2026
SCHEDULE 13D/A Amended ownership over 5% (active) Aug 3, 2026 —
144 Notice of proposed sale Aug 3, 2026 —
SCHEDULE 13D/A Amended ownership over 5% (active) Jul 31, 2026 —
144 Notice of proposed sale Jul 30, 2026 —
4 Insider transaction Jul 30, 2026 Jul 28, 2026
4 Insider transaction Jul 28, 2026 Jul 28, 2026
8-K Current report
Regulation FD disclosure, Other events
Jul 27, 2026 Jul 27, 2026
4 Insider transaction Jul 20, 2026 Jul 15, 2026
4 Insider transaction Jul 20, 2026 Jul 15, 2026
4 Insider transaction Jul 17, 2026 Jul 15, 2026
4 Insider transaction Jul 17, 2026 Jul 15, 2026
4 Insider transaction Jul 17, 2026 Jul 15, 2026
4 Insider transaction Jul 17, 2026 Jul 15, 2026
144 Notice of proposed sale Jul 17, 2026 —
144 Notice of proposed sale Jul 17, 2026 —
144/A Filing Jul 15, 2026 —
144 Notice of proposed sale Jul 15, 2026 —
144 Notice of proposed sale Jul 15, 2026 —
144 Notice of proposed sale Jul 15, 2026 —
144 Notice of proposed sale Jul 15, 2026 —
144 Notice of proposed sale Jul 15, 2026 —
144 Notice of proposed sale Jul 15, 2026 —
144 Notice of proposed sale Jul 15, 2026 —
4 Insider transaction Jun 25, 2026 Jun 23, 2026
4 Insider transaction Jun 25, 2026 Jun 23, 2026
4 Insider transaction Jun 25, 2026 Jun 23, 2026
4 Insider transaction Jun 25, 2026 Jun 23, 2026
4 Insider transaction Jun 25, 2026 Jun 23, 2026
4 Insider transaction Jun 25, 2026 Jun 23, 2026
3 Initial insider ownership Jun 25, 2026 Jun 23, 2026
3 Initial insider ownership Jun 25, 2026 Jun 23, 2026
8-K Current report
Shareholder vote results
Jun 24, 2026 Jun 23, 2026
8-K Current report
Regulation FD disclosure, Other events
Jun 22, 2026 Jun 22, 2026
8-K Current report
Officer or director change
Jun 18, 2026 Jun 18, 2026
4 Insider transaction May 18, 2026 May 18, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) May 15, 2026 —
10-Q Quarterly report May 14, 2026 Mar 31, 2026
8-K Current report
Results of operations, Regulation FD disclosure
May 14, 2026 May 14, 2026
4 Insider transaction May 11, 2026 May 11, 2026
4 Insider transaction May 11, 2026 May 7, 2026
4 Insider transaction May 11, 2026 May 7, 2026
4 Insider transaction May 11, 2026 May 7, 2026
4 Insider transaction May 6, 2026 May 4, 2026
4 Insider transaction May 6, 2026 May 4, 2026
4 Insider transaction May 6, 2026 May 4, 2026
4 Insider transaction May 6, 2026 May 4, 2026
4 Insider transaction May 6, 2026 May 4, 2026
144 Notice of proposed sale May 4, 2026 —
144 Notice of proposed sale May 4, 2026 —
144 Notice of proposed sale May 4, 2026 —
144 Notice of proposed sale May 4, 2026 —
144 Notice of proposed sale May 4, 2026 —
4 Insider transaction Apr 29, 2026 Apr 27, 2026
4 Insider transaction Apr 29, 2026 Apr 27, 2026
8-K Current report
Officer or director change
Apr 29, 2026 Apr 23, 2026
ARS Annual report to shareholders Apr 29, 2026 Dec 31, 2025
DEFA14A Additional proxy material Apr 29, 2026 —
DEF 14A Proxy statement Apr 29, 2026 Jun 23, 2026
144 Notice of proposed sale Apr 27, 2026 —
144 Notice of proposed sale Apr 27, 2026 —
4 Insider transaction Apr 17, 2026 Apr 15, 2026
4 Insider transaction Apr 17, 2026 Apr 15, 2026
4 Insider transaction Apr 17, 2026 Apr 15, 2026
4 Insider transaction Apr 17, 2026 Apr 15, 2026
4 Insider transaction Apr 17, 2026 Apr 15, 2026
4 Insider transaction Apr 17, 2026 Apr 15, 2026
4 Insider transaction Apr 17, 2026 Apr 15, 2026
4 Insider transaction Apr 17, 2026 Apr 15, 2026
144 Notice of proposed sale Apr 15, 2026 —
144 Notice of proposed sale Apr 15, 2026 —
144/A Filing Apr 15, 2026 —
144 Notice of proposed sale Apr 15, 2026 —
144/A Filing Apr 15, 2026 —
144/A Filing Apr 15, 2026 —
144/A Filing Apr 15, 2026 —
144 Notice of proposed sale Apr 15, 2026 —
144 Notice of proposed sale Apr 15, 2026 —
144 Notice of proposed sale Apr 15, 2026 —
144 Notice of proposed sale Apr 15, 2026 —
144 Notice of proposed sale Apr 15, 2026 —
S-8 Employee stock plan registration Mar 26, 2026 —
10-K Annual report Mar 26, 2026 Dec 31, 2025
8-K Current report
Results of operations, Regulation FD disclosure
Mar 26, 2026 Mar 26, 2026
4 Insider transaction Feb 24, 2026 Feb 20, 2026
144 Notice of proposed sale Feb 24, 2026 —
144 Notice of proposed sale Feb 23, 2026 —
4 Insider transaction Feb 20, 2026 Feb 18, 2026
144 Notice of proposed sale Feb 20, 2026 —
4 Insider transaction Feb 18, 2026 Feb 13, 2026
SCHEDULE 13G Ownership over 5% (passive) Feb 17, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Feb 17, 2026 —
144 Notice of proposed sale Feb 13, 2026 —
4 Insider transaction Feb 12, 2026 Feb 10, 2026
4 Insider transaction Feb 12, 2026 Feb 10, 2026
144 Notice of proposed sale Feb 11, 2026 —
144 Notice of proposed sale Feb 10, 2026 —
4 Insider transaction Feb 9, 2026 Feb 5, 2026
4 Insider transaction Feb 9, 2026 Feb 5, 2026
4 Insider transaction Feb 9, 2026 Feb 5, 2026
4 Insider transaction Feb 9, 2026 Feb 5, 2026
4 Insider transaction Feb 9, 2026 Feb 5, 2026
4 Insider transaction Feb 9, 2026 Feb 5, 2026
4 Insider transaction Feb 9, 2026 Feb 5, 2026
4 Insider transaction Feb 4, 2026 Feb 2, 2026
144 Notice of proposed sale Feb 3, 2026 —
144 Notice of proposed sale Feb 2, 2026 —
4 Insider transaction Jan 30, 2026 Jan 28, 2026
144 Notice of proposed sale Jan 30, 2026 —
4 Insider transaction Jan 29, 2026 Jan 27, 2026
4 Insider transaction Jan 29, 2026 Jan 27, 2026
4 Insider transaction Jan 29, 2026 Jan 27, 2026
4 Insider transaction Jan 29, 2026 Jan 27, 2026
4 Insider transaction Jan 29, 2026 Jan 27, 2026
4 Insider transaction Jan 29, 2026 Jan 27, 2026
4 Insider transaction Jan 29, 2026 Jan 27, 2026
144 Notice of proposed sale Jan 29, 2026 —
144 Notice of proposed sale Jan 28, 2026 —
8-K Current report
Results of operations, Regulation FD disclosure
Jan 9, 2026 Jan 9, 2026
10-Q Quarterly report Dec 4, 2025 Sep 30, 2025
8-K Current report
Results of operations, Regulation FD disclosure
Dec 4, 2025 Dec 4, 2025
SCHEDULE 13D Ownership over 5% (active) Nov 20, 2025 —
3/A Filing Nov 18, 2025 Oct 25, 2025
SCHEDULE 13D Ownership over 5% (active) Nov 4, 2025 —
4 Insider transaction Oct 30, 2025 Oct 28, 2025
4 Insider transaction Oct 29, 2025 Oct 28, 2025
8-K Current report
Unregistered share sale, Bylaw or fiscal year change, Other events
Oct 29, 2025 Oct 26, 2025
4 Insider transaction Oct 28, 2025 Oct 27, 2025
4 Insider transaction Oct 28, 2025 Oct 27, 2025
4 Insider transaction Oct 28, 2025 Oct 27, 2025
4 Insider transaction Oct 28, 2025 Oct 27, 2025
4 Insider transaction Oct 28, 2025 Oct 27, 2025
4 Insider transaction Oct 28, 2025 Oct 27, 2025
4 Insider transaction Oct 28, 2025 Oct 27, 2025
4 Insider transaction Oct 28, 2025 Oct 27, 2025
4 Insider transaction Oct 28, 2025 Oct 27, 2025
4 Insider transaction Oct 28, 2025 Oct 27, 2025
3 Initial insider ownership Oct 27, 2025 Oct 25, 2025
3 Initial insider ownership Oct 27, 2025 Oct 25, 2025
3 Initial insider ownership Oct 27, 2025 Oct 25, 2025
3 Initial insider ownership Oct 27, 2025 Oct 25, 2025
3 Initial insider ownership Oct 27, 2025 Oct 25, 2025
3 Initial insider ownership Oct 27, 2025 Oct 25, 2025
3 Initial insider ownership Oct 27, 2025 Oct 25, 2025
3 Initial insider ownership Oct 27, 2025 Oct 25, 2025
3 Initial insider ownership Oct 27, 2025 Oct 25, 2025
3 Initial insider ownership Oct 27, 2025 Oct 25, 2025
3 Initial insider ownership Oct 27, 2025 Oct 25, 2025
3 Initial insider ownership Oct 27, 2025 Oct 25, 2025
3 Initial insider ownership Oct 27, 2025 Oct 25, 2025
3 Initial insider ownership Oct 27, 2025 Oct 25, 2025
3 Initial insider ownership Oct 27, 2025 Oct 25, 2025
424B3 Prospectus Oct 27, 2025 —
S-8 Employee stock plan registration Oct 27, 2025 —
FWP Free writing prospectus Oct 27, 2025 —
CERT Filing Oct 24, 2025 —
8-A12B Filing Oct 24, 2025 —
FWP Free writing prospectus Oct 6, 2025 —
S-1/A Amended registration statement Oct 6, 2025 —
S-1 Registration statement Sep 19, 2025 —
DRSLTR Filing Aug 22, 2025 —
DRS/A Filing Aug 22, 2025 —
UPLOAD Letter from the SEC Aug 12, 2025 —
DRS/A Filing Jul 30, 2025 —
D Filing Jul 28, 2025 —
DRSLTR Filing May 10, 2024 —
DRS/A Filing May 10, 2024 —
UPLOAD Letter from the SEC Apr 24, 2024 —
DRSLTR Filing Apr 12, 2024 —
DRS/A Filing Apr 12, 2024 —

Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
MPLT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Redwood City, CA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1770069
Former names
Alvarado Therapeutics, Inc. (until Mar 22, 2019)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.